Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Age ≥18 years~2. LVEF ≤45% within the prior two years using any conventional imaging modality (this should be the most recent assessment of LVEF)~3. New York Heart Association (NYHA) class II - IV~4. Iron deficient - defined as TSAT \<20% and/or ferritin \<100 ug/L~5. Evidence of being in a higher risk HF group: (a) Current (with the expectation that patient will survive to discharge) or recent (within 6 months) hospitalisation for HF, OR (b) Out-patients with NT-proBNP \>250 ng/L in sinus rhythm or \>1,000 ng/L in atrial fibrillation (or BNP of \> 75 pg/mL or 300 pg/mL, respectively)~6. Able and willing to provide informed consent~Exclusion criteria~1. Haematological criteria: ferritin \>400ug/L; haemoglobin \<9.0, or \>13 g/dL in women or \>14g/dL in men; (B12 or folate deficiency should be corrected but do not exclude the patient)~2. MDRD/CKD-EPI estimated glomerular filtration rate (eGFR) \<15ml/min/1.73m2~3. Already planned to receive IV iron~4. Likely to need or already receiving erythropoiesis stimulating agents (ESA)~5. Any of the following apply: (a) planned cardiac surgery or revascularisation; (b) within 3 months of any of the following: a primary diagnosis of type 1 myocardial infarction (excluding small troponin elevations in the context of heart failure admissions), cerebrovascular accident (CVA), major CV surgery or percutaneous coronary intervention (PCI), or blood transfusion; (c) on active cardiac transplant list; (d) left ventricular assist device implanted.~6. Any of the following comorbidities: active infection (if the patient is suffering from a significant ongoing infection as judged by the investigator recruitment should be postponed until the infection has passed or is controlled by antibiotics), other disease with life expectancy of \<2 years, active clinically relevant bleeding in the investigator's opinion, known or suspected gastro-intestinal malignancy~7. Pregnancy, women of childbearing potential (i.e. continuing menstrual cycle) not using effective contraception (see Appendix 3) or breast-feeding women~8. Contra-indication to IV iron in the investigator's opinion according to current approved Summary of Product Characteristics: hypersensitivity to the active substance, to Monofer® or any of its excipients (water for injections, sodium hydroxide (for pH adjustment), hydrochloric acid (for pH adjustment)); known serious hypersensitivity to other parenteral iron products; non-iron deficiency anaemia (e.g. haemolytic anaemia); iron overload or disturbances in utilisation of iron (e.g. haemochromatosis, haemosiderosis); decompensated liver disease.~9. Participation in another intervention study involving a drug or device within the past 90 days (co-enrolment in observational studies is permitted)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard care (Type: NO_INTERVENTION): Participants in this arm will receive their usual care
- Standard care plus IV iron infusion (Type: EXPERIMENTAL): Iron to be administered as iron (III) isomaltoside 1000 / ferric derisomaltose.~Infused over a minimum of 15 mins for doses up to and including 1000mg, and a minimum of 30 mins for doses \>1000mg~Where Hb ≥10 g/dL, dosage according to body weight is as follows:~Body weight \<50 kg: 20 mg/kg; Body weight 50 to \<70 kg: 1000 mg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 1500 mg.~Where Hb \<10 g/dL, dosage according to body weight is as follows:~Body weight \<50 kg: 20 mg/kg; Body weight 50 to \<70 kg: 20 mg/kg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 2000 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).